Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTION-1: RYZ101 versus standard of care after prior lutetium-177 somatostatin analogue therapy in advanced SSTR-positive GEP-NETs
2023-509334-19-00Phase 3Authorised
- Sponsor
- RayzeBio
- Start
- Oct 2023
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial in gastroenteropancreatic neuroendocrine tumor (GEP-NET) comparing RYZ101 with Standard of care (2 arms). Primary endpoints: Dose-limiting toxicities, Safety and 1 more. Planned start Oct 2023; status: authorised.
02
Drugs
actinium-225 dotatate
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on 2023-509334-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509334-19-00.